ArticleCancer discovery2019
Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment.
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 228 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
228citing papers in PubMed, 1 pooled it
11.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
228 citing papers in PubMed, 1 synthesis or guideline pooled it, 331 citations in OpenAlex.
- The molecular mechanisms of mitochondrial dynamics and mitophagy and their complex association with cancer drug resistance.Journal of translational medicine · 2025Pooled it
- Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.Blood neoplasia · 2026Trial
- Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- ROCKing resistance: cytoskeletal mitochondrial synergy in acute myeloid leukemia.Haematologica · 2026Article
- Optimal Hypoxia Mimetic Small Molecules for Enhancing Angiogenic Properties of Stem Cells From Human Exfoliated Deciduous Teeth.International endodontic journal · 2026Article
- Pharmacological blockade of rho kinase enhances venetoclax responses in translational models of acute myeloid leukemia.Haematologica · 2026Article
- Rethinking Drug Resistance in Acute Promyelocytic Leukemia: The Regulated Cell Death Network as an Integrative Framework.Biomolecules · 2026Review
- Exploiting Metabolic Vulnerabilities in Acute Myeloid Leukemia: Rationale and Evidence for Combining Metabolic Modulators with Conventional Chemotherapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Paradoxical non-catalytic kinase functions are driven by inhibitor-induced displacement of autoinhibitory domains.Molecular systems biology · 2026Article
- HAX1 drives assembly and activation of the mitochondrial intermembrane space chaperone CLPB.bioRxiv : the preprint server for biology · 2026Article
- RBM15 and ZMYND8 shape acute myeloid leukemia response to BCL2 inhibitors.Haematologica · 2026Article
- m6A and NuRD complexes regulate monocytic differentiation and resistance to BCL2/BCL2L1 inhibitors in acute myeloid leukemia.Haematologica · 2026Article
- Dimethyl Fumarate Enhances Venetoclax-Induced Cell Death by Inhibiting Mitochondrial Respiration and Cell Cycle Control in Colorectal Cancer.Life (Basel, Switzerland) · 2026Article
- Specific FbioRxiv : the preprint server for biology · 2026Article
- Diagnosis-Driven Targeted Therapy in Acute Myeloid Leukemia: Clinical Integration of Tyrosine Kinase, BCL-2, and CD33-Directed Strategies with Midostaurin, Venetoclax, and Gemtuzumab Ozogamicin.Journal of clinical medicine · 2026Review
- β3-adrenergic blockade targets fatty acid oxidation to induce ferroptotic vulnerability in pediatric T-ALL.Biology direct · 2026Article
- Inhibition of ADSS2-mediated de novo AMP biosynthesis re-sensitizes acute myeloid leukemia to BH3 mimetics.Nature cancer · 2026Article
- From complexity to clarity: aging bone marrow niche in bone and blood regeneration and malignancy.Bone research · 2026Review
- Synergistic targeting of eIF4A-mediated translation initiation and apoptosis in acute myeloid leukemia.Blood neoplasia · 2026Article
- Acid ceramidase inhibition enhances BCL-2 targeting in venetoclax-resistant acute myeloid leukemia.Blood neoplasia · 2026Article
168 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
15 authors at 4 institutions in 1 country.
Xufeng Chen *Department of Pathology, NYU Langone Health and NYU School of Medicine, New York, New York.
Christina Glytsou *Department of Pathology, NYU Langone Health and NYU School of Medicine, New York, New York.ORCID 0000-0002-6260-338X
Hua ZhouApplied Bioinformatics Laboratories, NYU School of Medicine, New York, New York.
Sonali NarangLaura and Isaac Perlmutter Cancer Center, NYU Langone Health and NYU School of Medicine, New York, New York.
Denis E ReynaDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York.
Andrea LopezDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York.
Theodore SakellaropoulosDepartment of Pathology, NYU Langone Health and NYU School of Medicine, New York, New York.ORCID 0000-0001-9946-9498
Yixiao GongDepartment of Pathology, NYU Langone Health and NYU School of Medicine, New York, New York.
Andreas KloetgenDepartment of Pathology, NYU Langone Health and NYU School of Medicine, New York, New York.
Yoon Sing YapDepartment of Pathology, NYU Langone Health and NYU School of Medicine, New York, New York.
Eric WangDepartment of Pathology, NYU Langone Health and NYU School of Medicine, New York, New York.
Evripidis GavathiotisDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York.ORCID 0000-0001-6319-8331
Aristotelis TsirigosDepartment of Pathology, NYU Langone Health and NYU School of Medicine, New York, New York.ORCID 0000-0002-7512-8477
Raoul TibesLaura and Isaac Perlmutter Cancer Center, NYU Langone Health and NYU School of Medicine, New York, New York. Ioannis.Aifantis@nyumc.org Raoul.Tibes@nyumc.org.
Iannis AifantisDepartment of Pathology, NYU Langone Health and NYU School of Medicine, New York, New York. Ioannis.Aifantis@nyumc.org Raoul.Tibes@nyumc.org.
NYU Langone Health · USAlbert Einstein College of Medicine · USMemorial Sloan Kettering Cancer Center · USNew York University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MVaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1MTRAINING PROGRAM IN CELLULAR &MOLEC. BIOLOGY &GENETICST32GM007491 · NIGMS · YESHIVA UNIVERSITY · PI QUERY, CHARLES C · 1985 to 2021
$17.0MRole of TET2 mutations in malignant transformation and acute myeloid leukemiaR01CA173636 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI AIFANTIS, IANNIS, LEVINE, ROSS L · 2013 to 2022
$6.3MSmall Molecule Activators of Pro-apoptotic BAX for Cancer TherapyR01CA178394 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI GAVATHIOTIS, EVRIPIDIS · 2014 to 2024
$3.7MThe role of the SCF/FBW7 ubiquitin ligase complex in hematopiesis and leukemia.R01CA133379 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS · 2009 to 2018
$3.6MThe cohesin complex as a tumor suppressor in myeloid leukemiaR01CA216421 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS, LEVINE, ROSS L · 2017 to 2021
$2.5MMechanisms of enhancer regulation in leukemiaR01CA228135 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS · 2019 to 2023
$2.5MPost-translational control of cancer cell stress response and metastasisR01CA202027 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS, HERNANDO, EVA · 2016 to 2020
$2.3MGenetic Dissection of Acute Myeloid Leukemia.R01CA169784 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS, LEVINE, ROSS L · 2014 to 2018
$1.8MCHEK1 and WEE1 Inhibition as Therapeutic Strategies in AMLR01CA178979 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI TIBES, RAOUL · 2013 to 2018
$1.7MAcquisition of an Orbitrap Elite Mass Spectrometer with ETDS10OD010582 · OD · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI UEBERHEIDE, BEATRIX MAGDALENA · 2013 to 2013
$600kNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016087NCI NIH HHS R01 CA133379NCI NIH HHS R01 CA169784NCI NIH HHS R01 CA173636NCI NIH HHS R01 CA178394NCI NIH HHS R01 CA178979NCI NIH HHS R01 CA202027NCI NIH HHS R01 CA216421NCI NIH HHS R01 CA228135NCRR NIH HHS S10 RR023704NIGMS NIH HHS T32 GM007491NIH HHS S10 OD010582
Abstract
The BCL2 family plays important roles in acute myeloid leukemia (AML). Venetoclax, a selective BCL2 inhibitor, has received FDA approval for the treatment of AML. However, drug resistance ensues after prolonged treatment, highlighting the need for a greater understanding of the underlying mechanisms. Using a genome-wide CRISPR/Cas9 screen in human AML, we identified genes whose inactivation sensitizes AML blasts to venetoclax. Genes involved in mitochondrial organization and function were significantly depleted throughout our screen, including the mitochondrial chaperonin
Indexed as
AnimalsAntineoplastic AgentsApoptosisBridged Bicyclo Compounds, HeterocyclicCell Line, TumorClustered Regularly Interspaced Short Palindromic RepeatsDrug Resistance, NeoplasmEndopeptidase ClpGTP PhosphohydrolasesHEK293 CellsHeLa CellsHumansK562 CellsLeukemia, Myeloid, AcuteMiceMice, Inbred NODAntineoplastic AgentsBCL2 protein, humanBridged Bicyclo Compounds, HeterocyclicCLPB protein, humanEndopeptidase ClpGTP PhosphohydrolasesOPA1 protein, humanProto-Oncogene Proteins c-bcl-2Sulfonamidesvenetoclax
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.